Table 2.
Base case results.
| Outcomes | EP | AEP | DEP | Incremental | ||
|---|---|---|---|---|---|---|
| DEP vs AEP | AEP vs EP | DEP vs EP | ||||
| Cost, $US | 24,582 | 86,655 | 92,391 | 5,737 | 62,073 | 67,810 |
| QALY | 0.578 | 0.740 | 0.724 | −0.016 | 0.162 | 0.146 |
| ICER, $/QALY | Dominated a | 382,469 | 464,593 | |||
a
DEP showed lower effectiveness and higher cost, as compared with the AEP.
EP, etoposide plus platinum; AEP, atezolizumab combined with etoposide and platinum; DEP, durvalumab combined with etoposide and platinum; QALY, quality adjusted life year; ICER, incremental cost-effectiveness ratio.